Hospital Segment Underdog; Health Insurance–Icing on the cake
The current positioning of Narayana Hrudayalaya reflects a business that is consciously evolving from a hospital chain into a more resilient healthcare platform. The shift toward yield-led economics, the validation of integrated care through overseas operations, and the willingness to confront and correct execution challenges in complex markets underscore a management philosophy rooted in discipline rather than expediency. While capital intensity is set to rise as the next phase of growth is pursued, the underlying framework suggests that incremental investments are being made with a clear line of sight on long-term value creation. In this context, the present valuation appears to reflect caution on near-term transitions, while underappreciating the structural improvements that are steadily being embedded into the business model. This backdrop provides the context to evaluate the stock not merely on near-term performance, but on the durability and adaptability of its operating model across cycles and geographies.
Revised Buy Target Price of INR 2,750
We initiated coverage on Narayana Hrudayalaya on July 22, 2024, with a BUY recommendation at a CMP of ₹1,242 and a price target of ₹1,650, implying an upside of 32.85%. Subsequently, the stock delivered a substantial re-rating, scaling an all-time high of ₹2,371.6 on June 27, 2025, significantly surpassing our initial valuation construct. In light of the sharp price appreciation and elevated valuation multiples, we had prudently advised partial profit booking on June 30, 2025, at a CMP of ~₹2,150 to lock in gains. Post this peak, the stock has undergone a healthy correction in line with broader market volatility, bringing valuations back to more reasonable and defensible levels. At current prices, the stock appears to be trading close to its intrinsic value, factoring in NH’s strong execution track record, improving return ratios, asset-light expansion in select geographies, and sustained volume growth across key hospitals. We believe the recent correction offers a favorable re-entry opportunity, and hence, we reiterate our BUY recommendation from current levels, with valuation comfort restored and medium-term growth visibility intact we value NH 50x of its forecasted EPS of FY28 to arrive at our price target.
Report Attached.
Narayana_Hrudayalaya Ltd_Continuiing_Coverage_Report_FEB_14_2026